Imidazopyridine Carboxamides as Nurr-1 Modulators

The patent applies local quality by introducing specific heterocyclic groups at particular positions (R2 at position 6, X at position 2 of the imidazo[1,2-a]pyridine core) to enhance Nurr-1 binding affinity. Each substituent is strategically placed to interact with specific amino acid residues in the receptor binding pocket, thereby improving therapeutic effectiveness without uniformly complicating the entire molecular structure.

The patent employs composite materials by combining the imidazo[1,2-a]pyridine core structure with various heterocyclic groups (such as pyridine, pyrimidine, triazine rings) to create hybrid molecules with enhanced Nurr-1 modulator activity. This composite approach allows the molecule to leverage multiple structural features for improved binding and therapeutic effect.

The patent applies segmentation by dividing the molecule into modular components: a core imidazo[1,2-a]pyridine structure and separate heterocyclic substituent groups. This modular design allows each component to be synthesized independently using established methods, then assembled through coupling reactions, thereby managing synthesis complexity while maintaining high receptor affinity.

The patent utilizes parameter changes by systematically varying substituent types (different heterocyclic groups), their positions, and their electronic/steric properties to optimize Nurr-1 binding affinity. By adjusting these molecular parameters, the patent achieves high receptor affinity while selecting substituents that can be introduced through efficient synthetic transformations.